Intranasal administration of neuropeptide Y in man: systemic absorption and functional effects

  title={Intranasal administration of neuropeptide Y in man: systemic absorption and functional effects},
  author={J. Sylvain Lacroix and Alma Ricchetti and Denis R. Morel and B Mossimann and Bernard Waeber and Eric Grouzmann},
  journal={British Journal of Pharmacology},
1 Exogenous neuropeptide Y (NPY, 10 nmol, 50 nmol and 100 nmol) and its vehicle (NaCl 0.9%) were administered in a double blind, randomized and controlled manner by intranasal spray in 7 healthy volunteers. Variations of plasma NPY concentration over time were measured during 120 min. Forty min after the administration of 50 nmol and 100 nmol of exogenous NPY, plasma NPY increased from 5.5 ± 1.1 pM to 9.8 ± 2.3 pM (P < 0.05) and from 9.06 ± 5.1 pM to 20.8 ± 6.16 pM (P < 0.001), respectively… 

Functional effects of neuropeptide Y receptors on blood flow and nitric oxide levels in the human nose.

NPY is a potent vasoconstrictor in the human nose reducing mucosal blood flow, as well as the blood content, and intranasal nitric oxide (NO) concentration.

Post-exercise nasal vasoconstriction and hyporeactivity: possible involvement of neuropeptide Y.

Variations of plasma NPY concentrations over time correlated better with post-exercise nasal vasoconstriction and hyporeactivity to capsaicin than NA, suggesting that endogenous NPY could be involved in the prolonged post- exercise nasal vasocompletion and acts as a modulator of nasal airways reactivity.

Influence of TASP‐V, a novel neuropeptide Y (NPY) Y2 agonist, on nasal and bronchial responses evoked by histamine in anaesthetized pigs and in humans

It is concluded that intranasal or intrabronchial pretreatment with TASP‐V reduced nasal obstruction and bronchoconstriction evoked by histamine challenge in the pig and in healthy human volunteers, this agent attenuated NAR increase and MCSA reduction induced by intran asal application of histamine.

Neuropeptide Y (NPY).

Central functions of neuropeptide Y in mood and anxiety disorders

It is proposed that via this mode of administration, NPY might exert CNS therapeutic actions without untoward systemic effects, and the NPYergic system a promising target for the development of novel therapeutic interventions.

Neuropeptide Y: the universal soldier

NPY is involved in the regulatory loops that control food intake in the hypothalamus and appears also to be important for regulating the activity of neuroendocrine axes under poor metabolic conditions, which makes it an attractive target for the potential treatment of human diseases, such as obesity, metabolic disorders, hypertension and heart failure.

Neuropeptide Y (NPY) intranasal delivery alleviates Machado–Joseph disease

The findings support the translational potential of intranasal infusion of NPY as a pharmacological intervention in MJD and show a mitigation of motor and balance impairments through the analysis of mice behavioral tests.

Expression of NPY Y1 and CGRP1 Receptors in Human Nasal Mucosa: Implications in Allergic Rhinitis

The possibility of local release in connection with specific target receptors suggests a role for endogenous NPY and CGRP in the regulation of vascular tone, glandular secretion, and epithelial functions.



Neuropeptide Y (NPY) in human nasal mucosa.

Neuropeptide Y released from sympathetic neurons may play a role as a constrictor of arterial vessels and regulate vasomotor tone in the human nasal mucosa.

Compartment analysis of vascular effects of neuropeptides and capsaicin in the pig nasal mucosa.

The vasodilatory effect of Capsaicin, except the laser-Doppler signal, was markedly reduced by pretreatment with a combination of the ganglionic blocking agent chlorisondamine and atropine implying that capsaicin evokes a central reflex with a final parasympathetic pathway and release of agents like vasoactive intestinal polypeptide.

Modulation by neuropeptide Y of parasympathetic nerve‐evoked nasal vasodilatation via Y2 prejunctional receptor

It is concluded that sympathetic nerve stimulation attenuates parasympathetic vasodilatation via NPY release acting on prejunctional Y2 receptors.

Effect of neuropeptide Y on vasodilation mediated by calcitonin gene-related peptide (CGRP)-containing nerves in the mesenteric resistance vessel of the rat.

Results suggest that NPY modulates the release of CGRP from C GRP-containing nerves in mesenteric resistance vessels.

Neuropeptide Y as a Putative Modulator of the Vagal Effects on Heart Rate

It is concluded that neuropeptide Y release from cardiac sympathetic neurons depends on the frequency and duration, but not on the pattern, of sympathetic stimulation; is evoked even at physiological frequencies (2-5 Hz) of sympathetic activity; and is enhanced by a-adrenergic-receptor blockade, but is unaffected by β-adRenergic- receptor blockade.

Co-release and functional interactions of neuropeptide Y and noradrenaline in peripheral sympathetic vascular control.

  • J. Pernow
  • Biology
    Acta physiologica Scandinavica. Supplementum
  • 1988
The immunohistochemical results suggest that NPY-LI co-exists with NA in sympathetic periarterial nerves of skeletal muscle and that the released NPY may be the mediator of the adrenoceptor antagonist- and reserpine-resistant functional responses to SNS in the gracilis muscle.

Kinins are generated in vivo following nasal airway challenge of allergic individuals with allergen.

It is concluded that kinins are produced during local allergic reactions in the nose and may contribute to the symptomatology of the allergic response.